# Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (

Source: https://onco.cc/trials/nct07049926/  
OnCo record `nct07049926` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Belzutifan, Zanzalintinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) is a phase 1/2 interventional study registered as NCT07049926 by Merck Sharp & Dohme LLC, with 140 participants planned, started 2025-07-20 and due to reach its primary completion in 2031-10-26. Interventions recorded: Belzutifan, Zanzalintinib. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07049926
- Phase: 1/2
- Setting: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT07049926: https://clinicaltrials.gov/study/NCT07049926

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Belzutifan](https://onco.cc/drugs/belzutifan/), [Zanzalintinib](https://onco.cc/drugs/zanzalintinib/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07049926.json